160 related articles for article (PubMed ID: 32779246)
21. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.
Clifford SC; Lannering B; Schwalbe EC; Hicks D; O'Toole K; Nicholson SL; Goschzik T; Zur Mühlen A; Figarella-Branger D; Doz F; Rutkowski S; Gustafsson G; Pietsch T;
Oncotarget; 2015 Nov; 6(36):38827-39. PubMed ID: 26420814
[TBL] [Abstract][Full Text] [Related]
22. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens.
Yeo KK; Margol AS; Kennedy RJ; Hung L; Robison NJ; Dhall G; Asgharzadeh S
J Neurooncol; 2019 Nov; 145(2):375-383. PubMed ID: 31621042
[TBL] [Abstract][Full Text] [Related]
24. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
Gajjar A; Hernan R; Kocak M; Fuller C; Lee Y; McKinnon PJ; Wallace D; Lau C; Chintagumpala M; Ashley DM; Kellie SJ; Kun L; Gilbertson RJ
J Clin Oncol; 2004 Mar; 22(6):984-93. PubMed ID: 14970185
[TBL] [Abstract][Full Text] [Related]
25. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
26. Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221).
Lafay-Cousin L; Bouffet E; Strother D; Rudneva V; Hawkins C; Eberhart C; Horbinski C; Heier L; Souweidane M; Williams-Hughes C; Onar-Thomas A; Billups CA; Fouladi M; Northcott P; Robinson G; Gajjar A
J Clin Oncol; 2020 Jan; 38(3):223-231. PubMed ID: 31774708
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma.
Kumar R; Smith KS; Deng M; Terhune C; Robinson GW; Orr BA; Liu APY; Lin T; Billups CA; Chintagumpala M; Bowers DC; Hassall TE; Hansford JR; Khuong-Quang DA; Crawford JR; Bendel AE; Gururangan S; Schroeder K; Bouffet E; Bartels U; Fisher MJ; Cohn R; Partap S; Kellie SJ; McCowage G; Paulino AC; Rutkowski S; Fleischhack G; Dhall G; Klesse LJ; Leary S; Nazarian J; Kool M; Wesseling P; Ryzhova M; Zheludkova O; Golanov AV; McLendon RE; Packer RJ; Dunham C; Hukin J; Fouladi M; Faria CC; Pimentel J; Walter AW; Jabado N; Cho YJ; Perreault S; Croul SE; Zapotocky M; Hawkins C; Tabori U; Taylor MD; Pfister SM; Klimo P; Boop FA; Ellison DW; Merchant TE; Onar-Thomas A; Korshunov A; Jones DTW; Gajjar A; Ramaswamy V; Northcott PA
J Clin Oncol; 2021 Mar; 39(7):807-821. PubMed ID: 33502920
[TBL] [Abstract][Full Text] [Related]
28. Update on the integrated histopathological and genetic classification of medulloblastoma - a practical diagnostic guideline.
Pietsch T; Haberler C
Clin Neuropathol; 2016; 35(6):344-352. PubMed ID: 27781424
[TBL] [Abstract][Full Text] [Related]
29. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
[TBL] [Abstract][Full Text] [Related]
30. Treatment of pediatric average-risk medulloblastoma using craniospinal irradiation less than 2500 cGy and chemotherapy: single center experience in Korea.
Yoon JH; Park KD; Kang HJ; Kim H; Lee JW; Kim SK; Wang KC; Park SH; Kim IH; Shin HY
World J Pediatr; 2017 Aug; 13(4):367-373. PubMed ID: 28550392
[TBL] [Abstract][Full Text] [Related]
31. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
[TBL] [Abstract][Full Text] [Related]
32. Medulloblastoma comprises four distinct molecular variants.
Northcott PA; Korshunov A; Witt H; Hielscher T; Eberhart CG; Mack S; Bouffet E; Clifford SC; Hawkins CE; French P; Rutka JT; Pfister S; Taylor MD
J Clin Oncol; 2011 Apr; 29(11):1408-14. PubMed ID: 20823417
[TBL] [Abstract][Full Text] [Related]
33. Clinically unfavorable transcriptome subtypes of non-WNT/non-SHH medulloblastomas are associated with a predominance in proliferating and progenitor-like cell subpopulations.
Okonechnikov K; Schrimpf D; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M; Korshunov A
Acta Neuropathol; 2024 Jun; 147(1):95. PubMed ID: 38847845
[TBL] [Abstract][Full Text] [Related]
34. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM
Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928
[TBL] [Abstract][Full Text] [Related]
35. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
Pizer BL; Clifford SC
Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
[TBL] [Abstract][Full Text] [Related]
36. Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics.
Crosier S; Hicks D; Schwalbe EC; Williamson D; Leigh Nicholson S; Smith A; Lindsey JC; Michalski A; Pizer B; Bailey S; Bown N; Cuthbert G; Wharton SB; Jacques TS; Joshi A; Clifford SC
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):736-747. PubMed ID: 33826763
[TBL] [Abstract][Full Text] [Related]
37. Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement.
Bien-Willner GA; López-Terrada D; Bhattacharjee MB; Patel KU; Stankiewicz P; Lupski JR; Pfeifer JD; Perry A
Neuro Oncol; 2012 Jul; 14(7):831-40. PubMed ID: 22573308
[TBL] [Abstract][Full Text] [Related]
38. [Medulloblastoma. Pathology].
Siegfried A; Delisle MB
Neurochirurgie; 2021 Feb; 67(1):28-38. PubMed ID: 29703584
[TBL] [Abstract][Full Text] [Related]
39. Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response.
Friedrich C; Shalaby T; Oehler C; Pruschy M; Seifert B; Picard D; Remke M; Warmuth-Metz M; Kortmann RD; Rutkowski S; Grotzer MA; von Bueren AO
Childs Nerv Syst; 2017 Sep; 33(9):1463-1471. PubMed ID: 28695340
[TBL] [Abstract][Full Text] [Related]
40. Matching mice to malignancy: molecular subgroups and models of medulloblastoma.
Lau J; Schmidt C; Markant SL; Taylor MD; Wechsler-Reya RJ; Weiss WA
Childs Nerv Syst; 2012 Apr; 28(4):521-32. PubMed ID: 22315164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
